Trial Profile
A Single Arm Phase 2 Study of Talimogene Laherparepvec in Patients With Cutaneous Squamous Cell Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Oct 2018
Price :
$35
*
At a glance
- Drugs Talimogene laherparepvec (Primary)
- Indications Skin cancer; Squamous cell cancer
- Focus Therapeutic Use
- 25 Oct 2018 New trial record